Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurolog...

por Miller, Kathleen L., Fermaglich, Lewis J., Maynard, Janet
Publicado 2021

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development

por Miller, Kathleen L., Mueller, Christine, Liu, Gumei, Miller Needleman, Katherine I., Maynard, Janet
Publicado 2020

Anemia and the onset of gout in a population-based cohort of adults: Atherosclerosis Risk in Communities study

por McAdams-DeMarco, Mara A, Maynard, Janet W, Coresh, Josef, Baer, Alan N
Publicado 2012

Risk factors for incident hyperuricemia during mid-adulthood in African American and White men and women enrolled in the ARIC cohort study

por McAdams-DeMarco, Mara A, Law, Andrew, Maynard, Janet W, Coresh, Josef, Baer, Alan N
Publicado 2013

Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout

por Baer, Alan N., Kurano, Tracie, Thakur, Uma J., Thawait, Gaurav K., Fuld, Matthew K., Maynard, Janet W., McAdams-DeMarco, Mara, Fishman, Elliot K., Carrino, John A.
Publicado 2016